Skip to main content

Neumora Therapeutics, Inc.

NMRA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001885522

In the last 90 days, Neumora Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 113 institutions reported holding it in 13F filings for Q2 2026, worth $129.2M in total; no superinvestor holds it.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $701.6K in total
2
13F holdersQ2 2026, 0 vs. previous quarter
113
13F valueReported value at the end of Q2 2026
$129.2M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding NMRA, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding NMRA at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Neumora Therapeutics, Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 21, 2026 (view filing)7:10 PM ETAug 20-211 dayAurora Daljit SinghSee RemarksSSale−88.3K$1.53−$135.4K−64.4%48.8K after2 lots
Aug 21, 2026 (view filing)7:10 PM ETAug 20-211 dayAurora Daljit SinghSee RemarksSSale−87.8K$1.53−$134.6K−100.0%0 after2 lots
Aug 19, 2026 (view filing)7:17 PM ETAug 17-192 daysAurora Daljit SinghSee RemarksSSale−156.9K$1.55−$242.5K−76.3%48.8K after4 lots
Aug 19, 2026 (view filing)7:17 PM ETAug 17-192 daysAurora Daljit SinghSee RemarksSSale−120.9K$1.56−$189.2K−100.0%0 after3 lots
Feb 19, 2026 (view filing)Feb 172 daysAurora Daljit SinghSee RemarksSSale−6.17K$3.56−$21.9K−6.9%82.8K after
Feb 19, 2026 (view filing)Feb 172 daysPinto JoshuaPresidentSSale−5.97K$3.54−$21.1K−9.4%57.8K after
Feb 19, 2026 (view filing)Feb 172 daysBerns Paul LSee RemarksSSale−9.82K$3.51−$34.5K−0.1%7.40M after
Feb 19, 2026 (view filing)Feb 172 daysMilligan Michael LeeSee RemarksSSale−1.44K$3.57−$5.13K−6.4%21.0K after10b5-1
Nov 13, 2025 (view filing)Nov 112 daysAurora Daljit SinghSee RemarksSSale−114.7K$2.68−$307.4K−100.0%0 after10b5-1
Oct 29, 2025 (view filing)7:21 PM ETOct 272 daysCrandell Keith and 6 others10% OwnerPPurchase+1.92M$2.61+$5.00M+46.4%6.05M afterDuplicate filing

Top 10 13F holders, Q2 2026

The largest institutional positions in Neumora Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.

See all 113 holders
Institutions holding NMRA in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Siren, L.L.C.8,497,822$14.4M0.29%00.0%Unchanged
BlackRock, Inc.7,791,869$13.2M0.00%+5,737,553+279.3%Added
Softbank Group Corp6,090,301$10.4M0.06%00.0%Unchanged
Vanguard Capital Management LLC4,669,585$7.94M0.00%+777,692+20.0%Added
MIC Capital Management UK LLP4,460,700$7.58M1.92%00.0%Unchanged
FMR LLC3,498,869$5.95M0.00%+2110.0%Added
WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST3,309,123$5.63M0.06%00.0%Unchanged
Geode Capital Management, LLC2,607,289$4.43M0.00%+1,520,424+139.9%Added
ICONIQ Capital, LLC2,559,090$4.35M0.13%00.0%Unchanged
Two Sigma Investments, LP2,244,829$3.82M0.00%+208,137+10.2%Added